Primary Care Review of Actinic Keratosis and Its Therapeutic Options: A Global Perspective

Dermatology and Therapy

Volumn 5, Issue 1, 2015, Pages 19-35

  Chetty, Praven ^a   Choi, Felix ^b   Mitchell, Timothy ^c  

^a Beach Avenue Medical Clinic ^*  (Canada)

^b Balgowlah Skin Cancer Clinic   (Australia)

^c Montpelier Health Centre   (United Kingdom)

Author keywords

Actinic keratosis; Awareness; Field directed; Lesion directed; Non melanoma skin cancer; Primary care; Squamous cell carcinoma; Topical treatment

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE; SUNSCREEN;

ABLATION THERAPY; ACTINIC KERATOSIS; AUSTRALIA; AWARENESS; CANADA; COMPARATIVE STUDY; CRYOSURGERY; CURETTAGE; EXCISION; GENERAL PRACTITIONER; HEALTH CARE COST; HUMAN; INCIDENCE; JOB EXPERIENCE; LOW LEVEL LASER THERAPY; MALIGNANT TRANSFORMATION; PATIENT EDUCATION; PHOTODYNAMIC THERAPY; PREVALENCE; PRIMARY HEALTH CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SKIN CARCINOMA; UNITED KINGDOM;

EID: 84925759956     PISSN: 21938210     EISSN: 21909172     Source Type: Journal    
DOI: 10.1007/s13555-015-0070-9     Document Type: Review

References (50)

1. Uhlenhake EE. Optimal treatment of actinic keratoses. Clin Interv Aging. 2013;8:29–35.
2. Schmitt JV, Miot HA. Actinic keratosis: a clinical and epidemiological revision. An Bras Dermatol. 2012;87:425–34.
3. Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M. Non-melanoma skin cancer and solar keratoses II analytical results of the South Wales Skin Cancer Study. Br J Cancer. 1996;74:1308–12.
4. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:S8–10.
5. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42:23–4.
6. Rigel DS. Stein Gold LF. The importance of early diagnosis and treatment of actinic keratosis. J Am Acad Dermatol. 2013;68(Suppl 1):S20–7.
7. Rosen T, Lebwohl MG. Prevalence and awareness of actinic keratosis: barriers and opportunities. J Am Acad Dermatol. 2013;68:S2–9.
8. Berger DS, Urbach F. A climatology of sunburning ultraviolet radiation. Photochem Photobiol. 1982;35:187–92.
9. Nestor MS, Zarraga MB. The incidence of nonmelanoma skin cancers and actinic keratoses in South Florida. J Clin Aesthet Dermatol. 2012;5:20–4.
10. Marks R. Freckles, moles, melanoma and the ozone layer: a tale of the relationship between humans and their environment. Med J Aust. 1989;151:611–3.
11. de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156:222–30.
12. Babilas P, Landthaler M, Szeimies RM. Actinic keratoses. Hautarzt. 2003;54:551–60.
13. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:4–7.
14. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000;142:1154–9.
15. Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012;12:CD004415.
16. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68:957–66.
17. MacKie RM. Awareness, knowledge and attitudes to basal cell carcinoma and actinic keratoses among the general public within Europe. J Eur Acad Dermatol Venereol. 2004;18:552–5.
18. Halpern AC, Hanson LJ. Awareness of, knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians. Int J Dermatol. 2004;43:638–42.
19. The Lewin Group Inc. for The Society for Investigative Dermatology and The American Academy of Dermatology Association. The burden of skin diseases. Available from: http://www.lewin.com/~/media/Lewin/Site_Sections/Publications/april2005skindisease.pdf. Last accessed April 22, 2013.
20. Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol. 2013;68(Suppl 1):S28–38.
21. Naylor MF, Boyd A, Smith DW, Cameron GS, Hubbard D, Neldner KH. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol. 1995;131:170–5.
22. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993;329:1147–51.
23. van der Pols JC, Williams GM, Pandeya N, Logan V, Green AC. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomark Prev. 2006;15:2546–8.
24. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol. 2008;18:651–9.
25. Reeve T. Cancer Council Australia 2008 Clinical Practice Guide Basal cell carcinoma, squamous cell carcinoma (and related lesions): a guide to clinical management in Australia. Available from: http://www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/Basal_cell_carcinoma_Squamous_cell_carcinoma_Guide_Nov_2008-Final_with_Corrigendums.pdf. Last accessed Nov 8, 2013.
26. Schumack PS. Australian Prescriber: non-surgical treatments for skin cancer. Available from: http://www.australianprescriber.com/magazine/34/1/6/7. Last accessed Nov 8, 2013.
27. Chia A, Moreno G, Lim A, Shumack S. Actinic keratoses. Aust Fam Physician. 2007;36:539–43.
28. Sterry W. European Dermatology Forum Guideline on Actinic Keratosis. Available from: http://www.ensas.ee/docs/management_of_actinic_keratoses.pdf. Last accessed Nov 8, 2013.
29. Pharmaderm. Solaraze gel. Prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021005s013lbl.pdf. Last accessed April 10, 2014.
30. Jenerowicz D, Jabubowicz O, Polanska A, Sadowska A, Danczak-Pazdrowska A, Zaba R. Photosensitivity to selected topical nonsteroidal anti-inflammatory drugs preparations—a review of literature data and author’s own experience. Cent Eur J Immunol. 2013;36:197–203.
31. Electronic Medicines Consortium (eMC). Solaraze SmPC. Available from: http://www.medicines.org.uk/emc/medicine/21229/SPC. Last accessed April 10, 2014.
32. 3M Health Care Limited. Aldara (Imiquimod): Highlights of prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020723s020lbl.pdf. Last accessed June 4, 2014.
33. Stockfleth E, Sterry W, Carey-Yard M, Bichel J. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol. 2007;157(Suppl 2):41–6.
34. Jorizzo JL, Markowitz O, Lebwohl MG, et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol. 2010;9:1101–8.
35. Martin G, Swanson N. Clinical findings using ingenol mebutate gel to treat actinic keratoses. J Am Acad Dermatol. 2013;68(1 Suppl 1):S39–48.
36. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010–9.
37. Lebwohl M, Shumack S, Gold LS, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149:666–70.
38. Dosik JS, Damstra M, Udell C, Welburn P. Evaluation of the skin sensitization, photoirritation, and photoallergic potential of ingenol mebutate gel in healthy volunteers. J Clin Aesthet Dermatol. 2014;7:35–42.
39. Berman B, Goldenberg G, Hanke W, et al. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results. J Drugs Dermatol. 2014;13:154–60.
40. Berman B, Goldenberg G, Hanke CW, et al. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results. J Drugs Dermatol. 2014;13:741–7.
41. Wolf JE Jr, Rigel DS. Understanding efficacy end-points in studies of field-directed therapy for actinic keratosis. Int J Dermatol. 2013;52:1063–70.
42. Garside R, Pearson M, Moxham T. What influences the uptake of information to prevent skin cancer? A systematic review and synthesis of qualitative research. Health Educ Res. 2010;25:162–82.
43. Tran DT, Salmon R. Field treatment of facial and scalp actinic keratoses with photodynamic therapy: survey of patient perceptions of treatment satisfaction and outcomes. Australas J Dermatol. 2011;52:195–201.
44. Streeton CL, Gospodarevskaya E, Harris AH. How are solar keratoses treated by general practitioners in Australia? Int J Dermatol. 2006;45:272–6.
45. Primary Care Dermatology Society. Actinic keratosis (syn. solar keratosis). Available from: http://www.pcds.org.uk/clinical-guidance/actinic-keratosis-syn.-solar-keratosis. Last accessed April 17, 2014.
46. Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications—actinic keratoses, Bowen’s disease, basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013;27:536–44.
47. Wiegell SR, Wulf HC, Szeimies RM, et al. Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol. 2012;26:673–9.
48. National Institute for Health and Care Excellence (NICE). Actinic keratosis ingenol mebutate gel. Available from: http://www.nice.org.uk/advice/esnm14. Last accessed Jan 20, 2014.
49. Scottish Medicines Consortium. Briefing note: ingenol mebutate gel (Picato). Available from: http://www.scottishmedicines.org.uk/SMC_Advice/Advice/851_13_ingenol_mebutate_gel_Picato/Briefing_note_ingenol_mebutate_gel_Picato. Last accessed April 11, 2014.
50. AmirthaVani BP, Charles-Holmes R, Humphreys F, Bedlow AJ, Gee BC, Benjamin M. Evaluation of the dermatology outpatient service: a general practitioners’ questionnaire survey about the quality of outpatient consultations. Br J Dermatol. 2005;153:44–5.